Nina Isoherranen - Selected Publications

Thatcher JE, Isoherranen N. "The role of CYP26 enzymes in retinoic acid clearance." Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):875-86. Full article

Isoherranen N, Hachad H, Yeung CK, Levy RH. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol. 2009 Feb;22(2):294-8.

Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, Nelson WL, Isoherranen N.Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochem Pharmacol. 2009 Jan 15;77(2):258-68. Epub 2008 Oct 17. Full Article
Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF and Isoherranen N. "Changes in Maternal Liver CYP2C and CPY2D Expression and Activity During Rat Pregnancy" Biochem Pharmacol. 2008 Apr 15;75(8):1677-87. Epub 2008 Feb 7.

Isoherranen N, Givens RC, Ludington SS, Hawke RL, Pusek SN, Dees C, Blough D, Iwanaga K, Schuetz E, Watkins PB, Thummel KE and Paine MF. "Influence of CYP3A5 genotype on the extent of CYP3A inhibition in healthy African Americans" Drug Metab Dispos 2008 36:146-154.

Templeton I, Kharasch E, Kunze KL, Hoffer C, Nelson W and Thummel KE and Isoherranen N. Role of itraconazole metabolites in CYP3A4 inhibition in vivo. Clin Pharmacol Ther 2007.

Pearson JT, Hill JJ, Swain J, Isoherranen N, Kunze KL and Atkins WM. Surface plasmon Resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orietations. Biochemistry 2006 45:6341-6353.

Kunze KL, Nelson WL, Kharasch ED, Thummel KE, Isoherranen N. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos. 2006 Apr;34(4):583-90. Epub 2006 Jan 13.

Isoherranen N, Kunze KL, Allen KE, Nelson WL and Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 32 :1121-1131, 2004.

Isoherranen N, Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, Roeder M, Tripplett A, Schurig V and Finnell RH. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)- a -ethyl-oxo-pyrrolidine acetate in a mouse model of teratogenicity. Epilepsia 44: 1280-1288, 2003.

Isoherranen N, White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, Yagen B and Bialer M. Pharmacokinetic-Pharmacodynamic relationships of (2S,3S)-Valnoctamide and its stereoisomer (2R,3S)-Valnoctamide in rodent models of epilepsy. Pharm Res 20: 1293-1301, 2003.

Isoherranen N, White HS, Finnell RH, Woodhead JH, Yagen B, Bennett GD, Wilcox KE, Barton ME and Bialer M. Anticonvulsant Activity and Teratogenicity of N-methyl tetramethylcyclopropyl carboxamide. Epilepsia 43:115-126, 2002.